Alliance for Pandemic Preparedness
May 13, 2021
Persisting Salivary IgG against SARS-CoV-2 at 9 Months After Mild COVID-19: A Complementary Approach to Population Surveys
Category: Article Summary
Topic: Testing and Treatment
Keywords (Tags): testing
- Anti-SARS-CoV-2 spike IgG antibodies were detectable in >85% of saliva samples obtained from 74 mostly mild COVID-19 patients up to 9 months-post symptom onset. Salivary IgG responses were highly correlated with anti-spike IgG. In contrast, anti-nucleocapsid IgG was much lower in samples collected 3 months post symptom onset. In a separate cohort of 147 asymptomatic individuals, only 14-15% had salivary IgG, which was more common among those self-reporting COVID-19-like symptoms prior to saliva sampling.
Alkharaan et al. (May 12, 2021). Persisting Salivary IgG against SARS-CoV-2 at 9 Months After Mild COVID-19: A Complementary Approach to Population Surveys. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiab256